PET Radiopharmaceuticals for Tumor Imaging

Introduction to PET Radiopharmaceuticals

The European Association of Nuclear Medicine recommends the use of 18F-FDG (Fluorodeoxyglucose) as the most widely used PET radiopharmaceutical in oncology, exploiting increased glucose metabolism in cancer cells through upregulated GLUT1 transporters and hexokinase activity 1, 2

The American College of Radiology suggests 18F-FDG for staging, restaging, and treatment response assessment in lung and pleural cancers, lymphomas, melanoma, head and neck cancers, gastrointestinal cancers, gynecological cancers, soft tissue and bone sarcomas, and carcinoma of unknown primary 1, 3, 4
The National Comprehensive Cancer Network recommends 18F-FDG for response assessment with pooled sensitivity 84% for Hodgkin's lymphoma and 72% for aggressive non-Hodgkin's lymphoma, including DLBCL 5

The Society of Nuclear Medicine and Molecular Imaging advises waiting at least 2-3 months after radiation therapy to minimize false-positive inflammatory uptake 5
The European Association of Nuclear Medicine recommends imaging should occur 5-20 minutes post-injection with 10-20 minute acquisition times 6

The European Journal of Nuclear Medicine and Molecular Imaging suggests 11C-Methionine demonstrates superior performance for brain tumor imaging with 87% sensitivity and 89% specificity, outperforming MRI alone and providing excellent tumor-to-background contrast due to low normal brain uptake 7
The American College of Radiology recommends 18F-FET (O-(2-[18F]fluoroethyl)-L-tyrosine) for brain metastases imaging, glioma evaluation, and treatment response monitoring 6

The Journal of Clinical Oncology recommends 68Ga-PSMA-11 (PSMA-HBED-CC) for intermediate- to high-risk primary prostate cancer, biochemical recurrence after definitive therapy, delineation of metastatic disease extent, and patient eligibility assessment for PSMA-targeted radioligand therapy 8, 9
The National Comprehensive Cancer Network suggests 11C-Choline and 18F-Choline for biochemical recurrence of prostate cancer, though PSMA tracers have largely superseded it 8, 9

The European Journal of Nuclear Medicine and Molecular Imaging recommends compliance with QIBA (Quantitative Imaging Biomarkers Alliance) standards to enhance reproducibility 10
The Society of Nuclear Medicine and Molecular Imaging advises against relying on negative FDG-PET alone, as false negatives occur regularly, and biopsy confirmation is required for cancer diagnosis 8, 9

The American Urological Association recommends PSMA PET as the most sensitive imaging modality for detecting biochemically recurrent prostate cancer and should be performed instead of or after negative conventional imaging 11
The National Comprehensive Cancer Network suggests that next generation molecular PET imaging (primarily PSMA) should be performed for patients with biochemical recurrence following radical prostatectomy in whom salvage radiation is being considered 11

The National Comprehensive Cancer Network recommends that FDG PET has limited utility in routine prostate cancer evaluation and is not recommended for standard staging or restaging 12, 13, 14
The American College of Radiology notes that FDG PET identified local or metastatic disease in only 31% of patients with biochemical recurrence after radical prostatectomy, demonstrating poor sensitivity compared to PSMA tracers 15

The American College of Radiology suggests that as advanced metastatic prostate cancer migrates to high Gleason grade, dedifferentiates, or transforms to aggressive variants, tumor cells convert to higher glucose metabolism, making FDG useful in this subset of patients 16, 15
The Journal of Urology recommends that a subset of prostate cancer may not produce PSA or express PSMA, particularly poorly differentiated or neuroendocrine prostate cancer; in these instances, 18F-fluciclovine-PET/CT or FDG-PET may be useful 11
The Journal of Clinical Oncology notes that PSMA-negative primary tumor occurs in 5-10% of cases, where FDG may provide complementary information 17, 18